First, back away from the 10X zoom mirror.

There are few things more humbling than stepping outside after doing your makeup and realising your foundation doesn’t match your neck, your blush is far more intense than intended, and somehow your ...

Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.5% in the afternoon session after several analysts raised their price targets on the stock, pointing to a more optimistic outlook for the ...

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 6.3% in the morning session after Citigroup downgraded the stock to Neutral from Buy. The analyst firm adjusted its rating on the life science ...

Taich stated, "We anticipate revenue to be in the range of $154 million to $158 million, representing 5% growth compared to Q3 at the midpoint." He explained, "We do not anticipate a material change ...

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates - ...

10x Genomics is upgraded from 'Sell' to 'Hold' after a significant price drop and improved profitability, aided by a favorable Bruker settlement. TXG's Q2 profitability is driven by $68 million in ...

For content to make a real impact, it can no longer just be better—it has to be exponentially better. Search results are saturated, readers are increasingly skeptical, and Google is heavily ...

The company’s Q2 earnings project an ARR of up to $1.1 billion, fueling speculation about its 10x growth potential. NBIS’ rapidly growing revenue base argues for it being the most undervalued AI stock ...

PLEASANTON, Calif. - 10x Genomics, Inc. (NASDAQ:TXG), currently trading at $12.80 with a market capitalization of $1.57 billion, announced today it has signed a definitive agreement to acquire Scale ...

Following version 2.0 at Made by Google last year, the latest update to Pixel Magnifier introduces live text search. In addition to live search, Google has also improved the “Back and Restore” ...

Investors usually find it discouraging when an analyst cuts the price target on one of their stocks. In this instance, the cut to this company's shares was rather deep. It wasn't immediately apparent ...